Similarly, the levels of TAZ and YAP were elevated in mice and human patients with NASH.333 One of the underlying mechanisms by which YAP/TAZ is increased in NASH may be related to the suppression of TAZ degradation mediated by β-TrCP-mediated ubiquitination and degradation.334. This evidence concerns the gene YAP1 and metabolic dysfunction-associated steatohepatitis.